Regulatory reference: | UNI EN 14683:2019. |
Claim: | Determination of breathability |
Application field: | Raw materials and finished products. |
Description of the test: | Determination of the differential pressure is an indicator of the “breathability” of the mask. Air permeability is measured by determining the pressure difference across the mask under specific conditions of airflow, temperature and humidity. |
Regulatory reference: | ISO 10993-23:2021. |
Claim: | Biocompatible |
Application field: | Raw materials and finished products. |
Description of the test: | In vitro skin irritation test for solid medical devices according to ISO 10993-23:2021. |
Regulatory reference: | UNI EN ISO 11737-1:2018 and UNI EN 14683:2019. |
Claim: | Determination of bacterial charge |
Application field: | Raw materials and finished products. |
Description of the test: | The Bioburden analysis is designed to determine the microbiological cleanliness of medical face masks in order to evaluate their suitability for medical usage. |
Regulatory reference: | ISO 14683:2019 (B). |
Claim: | BFE (Bacterial Filtration Efficiency) |
Application field: | Raw materials and finished products. |
Description of the test: | Bacterial Filtration Efficacy (BFE) testing according to EN 14683:2019 (B) through Andersen six stage viable impactor. The analysis is performed on textile samples for the production of surgical masks or on finished surgical masks. |
Regulatory reference: | Proprietary method |
Claim: | Protects and repairs the cutaneous barrier |
Application field: | Topical products. |
Description of the test: | Evaluation on 3D in vitro epidermis of the efficacy of a product in protecting against acids, alkalis or solvents. |
Regulatory reference: | Proprietary method |
Claim: | Protects and repairs the cutaneous barrier |
Application field: | Topical products. |
Description of the test: | Evaluation of the protective efficacy against acids, alkalis or solvents on in vitro 3D human epidermis, paired with evaluation of the protection against pro-inflammatory substances. |
Regulatory reference: | Proprietary method |
Claim: | Barrier effect |
Application field: | Solutions or finished products. |
Description of the test: | Quantification by HPLC of the amount of caffeine permeating the skin barrier of in vitro 3D skin in Franz’s cells, compared to the total titer of the same substance in the applied product. |
Regulatory reference: | Proprietary method |
Claim: | Barrier effect |
Application field: | Solutions or finished products. |
Description of the test: | Quantification by HPLC of the amount of testosterone permeating the skin barrier of in vitro 3D skin in Franz’s cells, compared to the total titer of the same substance in the applied product. |
Regulatory reference: | Proprietary method |
Claim: | Protects and repairs the cutaneous barrier |
Application field: | Topycal products. |
Description of the test: | Measurement of inhibitory efficacy of an active ingredient or finished product against the adhesion of Staphylococcus aureus to epithelial cells. |
Regulatory reference: | Proprietary method |
Claim: | Inhibition of bacterial adhesion |
Application field: | Raw ingredients or finished products. |
Description of the test: | Measurement of inhibitory efficacy of an active ingredient or finished product against the adhesion of Staphylococcus aureus to epithelial cells. |